Intracerebral hemorrhage is the sudden burst of blood into the brain tissue itself.
It causes sudden onset of focal neurological deficit.
The focal neurologic findings are related to the anatomic location, size and speed of development of intracerebral hemorrhage.
Neurological deficit usually progresses over a minute to an hour.
Rapid recognition and diagnosis of intracerebral hemorrhage are essential because of its frequently rapid progression.
New drug applications approved by US FDA as of 01 - 15 January 2021 which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
A multicenter trial to investigate whether antithrombotic therapy can be initiated in atrial fibrillation (AF) patients who have survived an intracerebral haemorrhage (ICH) can be done, based on the results of the phase II feasibility trial NASPAF-ICH* presented at the 2020 International Stroke Conference (ISC).
Asian ischaemic stroke patients with small and fragile cerebral vessels, as evidenced by the presence of multiple cerebral microbleeds (CMBs), may fare better with cilostazol than aspirin, as the former proves more effective at preventing cerebral haemorrhages especially when administered before white matter changes become extensive, according to the results of a subgroup analysis of the PICASSO* trial.
Restarting antiplatelet therapy in survivors of intracranial haemorrhage (ICH)-related stroke is safe without raising their risk of a recurrent ICH, contrary to the commonly perceived risk of a recurrence with an antithrombotic drug, the RESTART* trial has shown.
A dual antiplatelet therapy (DAPT) of aspirin and clopidogrel significantly prevented the recurrence of major ischaemic events within 90 days following a minor stroke compared with aspirin alone, albeit this comes at the cost of increased major bleeding risk, according to the POINT* study.
Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.
Combining the anticoagulant rivaroxaban with aspirin reduces the risk of ischaemic stroke by almost half without a significant increase in the risk of intracerebral haemorrhage (ICH) or haemorrhagic transformation compared with aspirin alone in patients with stable coronary artery disease (CAD), according to new data from the COMPASS* study presented at ISC 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.